This Study Looks at the Effects of Idarucizumab in Patients Who Take Dabigatran and Need Emergency Surgery or Are Bleeding

PHASE3CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

March 26, 2018

Primary Completion Date

July 2, 2020

Study Completion Date

July 2, 2020

Conditions
Hemorrhage
Interventions
DRUG

Idarucizumab

Intravenous

Trial Locations (13)

100029

Beijing AnZhen Hospital, Beijing

100034

Peking University First Hospital, Beijing

100037

Cardiovascular Institute and Fu Wai Hospital, Beijing

116011

First Affiliated Hospital of Dalian Medical University, Dalian

200080

Shanghai First People's Hospital, Shanghai

210029

Jiangsu Province Hospital, Nanjing, Jiangsu Province

310009

2nd Affiliated Hosp Zhejiang University College of Medical, Hangzhou

310014

Zhejiang Province People's Hospital, Hangzhou

325000

The First Affiliated Hospital of Wenzhou Med College, Wenzhou

330006

The Second Affiliated Hospital to Nanchang University, Nanchang

510080

Guangdong Provincial People's Hospital, Guangzhou

510288

Sun yet-sen Memorial Hospital, Sun yet-sen Univesity, Guangzhou

830054

The First Affiliated Hospital of Xinjiang Medical University, Ürümqi

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT03343704 - This Study Looks at the Effects of Idarucizumab in Patients Who Take Dabigatran and Need Emergency Surgery or Are Bleeding | Biotech Hunter | Biotech Hunter